Evidence map›Paper›PMID 27692545›Full record

ArticleBioorganic & medicinal chemistry letters2016

Design, synthesis, and biological evaluation of α-hydroxyacyl-AMS inhibitors of amino acid adenylation enzymes.

Tony D Davis, Poornima Mohandas, Maria I Chiriac, Glennon V Bythrow, Luis E N Quadri, Derek S Tan

Open access · greenAbstract read
In one paragraph

Article in Bioorganic & medicinal chemistry letters, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Targeting Siderophore Biosynthesis to Thwart Microbial Growth.International journal of molecular sciences · 2025
    Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Tony D DavisPharmacology Program, Weill Cornell Graduate School of Medical Sciences, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 422, New York, NY 10065, United States.
Poornima MohandasDepartment of Biology, Brooklyn College, City University of New York, 2900 Bedford Avenue, Brooklyn, NY 11210, United States; Biology Program, Graduate Center, City University of New York, 365 Fifth Avenue, New York, NY 10016, United States.
Maria I ChiriacChemical Biology Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 422, New York, NY 10065, United States.
Glennon V BythrowDepartment of Biology, Brooklyn College, City University of New York, 2900 Bedford Avenue, Brooklyn, NY 11210, United States; Biology Program, Graduate Center, City University of New York, 365 Fifth Avenue, New York, NY 10016, United States.
Luis E N QuadriDepartment of Biology, Brooklyn College, City University of New York, 2900 Bedford Avenue, Brooklyn, NY 11210, United States; Biology Program, Graduate Center, City University of New York, 365 Fifth Avenue, New York, NY 10016, United States.
Derek S TanPharmacology Program, Weill Cornell Graduate School of Medical Sciences, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 422, New York, NY 10065, United States; Chemical Biology Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 422, New York, NY 10065, United States; Tri-Institutional Research Program, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 422, New York, NY 10065, United States.
Memorial Sloan Kettering Cancer Center · USThe Graduate Center, CUNY · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
UCSD/SDSU IRACDAK12GM068524 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TREJO, JOANN · 2003 to 2025
$24.4M
CANCER PHARMACOLOGYT32CA062948 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI LORRAINE J GUDAS · 1994 to 2026
$12.1M
Rational Design of Adenylation Enzyme InhibitorsR01GM100477 · NIGMS · SLOAN-KETTERING INST CAN RESEARCH · PI TAN, DEREK S · 2012 to 2015
$1.8M
NCI NIH HHS P30 CA008748NCI NIH HHS T32 CA062948NIGMS NIH HHS K12 GM068524NIGMS NIH HHS R01 GM100477
6 · The paper itself

Abstract

Biosynthesis of bacterial natural-product virulence factors is emerging as a promising antibiotic target. Many such natural products are produced by nonribosomal peptide synthetases (NRPS) from amino acid precursors. To develop selective inhibitors of these pathways, we have previously described aminoacyl-AMS (sulfamoyladenosine) macrocycles that inhibit NRPS amino acid adenylation domains but not mechanistically-related aminoacyl-tRNA synthetases. To improve the cell permeability of these inhibitors, we explore herein replacement of the α-amino group with an α-hydroxy group. In both macrocycles and corresponding linear congeners, this leads to decreased biochemical inhibition of the cysteine adenylation domain of the Yersina pestis siderophore synthetase HMWP2, which we attribute to loss of an electrostatic interaction with a conserved active-site aspartate. However, inhibitory activity can be regained by installing a cognate β-thiol moiety in the linear series. This provides a path forward to develop selective, cell-penetrant inhibitors of the biosynthesis of virulence factors to probe their biological functions and potential as therapeutic targets.

Indexed as

AdenosineAmino AcidsEnzyme InhibitorsPeptide SynthasesStructure-Activity RelationshipAdenosineAmino AcidsEnzyme Inhibitorsnon-ribosomal peptide synthasePeptide SynthasesAdenylationAntibioticNon-ribosomal peptide synthetaseRational designVirulence

Identifiers

PMID27692545
PMCPMC5079767
OpenAlexW2519712559

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.